{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T18:23:05Z","timestamp":1793125385097,"version":"4.5.0"},"reference-count":301,"publisher":"MDPI AG","issue":"16","license":[{"start":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T00:00:00Z","timestamp":1787011200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100010621","name":"Medical University of Lublin","doi-asserted-by":"crossref","award":["DS640"],"award-info":[{"award-number":["DS640"]}],"id":[{"id":"10.13039\/501100010621","id-type":"DOI","asserted-by":"crossref"}]},{"award":["DS640"],"award-info":[{"award-number":["DS640"]}],"id":[{"id":"https:\/\/ror.org\/016f61126","id-type":"ROR","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Gastrointestinal (GI) cancers represent a diverse group of malignancies that remain a major cause of cancer-related morbidity and mortality worldwide. Their management is increasingly complex, reflecting differences in tumor biology, anatomical location, stage, and molecular profile. In recent years, advances in molecular diagnostics, immunotherapy, and targeted treatment have moved clinical decision-making beyond a purely organ- and stage-based approach toward more individualized, biomarker-guided care. This narrative review summarizes established and emerging biological and targeted therapies used in esophageal, gastric and gastroesophageal junction, colorectal, pancreatic, hepatocellular, and biliary tract cancers. It focuses on immune checkpoint inhibitors targeting PD-1, PD-L1, and CTLA-4; HER2-directed monoclonal antibodies and antibody\u2013drug conjugates; antiangiogenic and anti-EGFR therapies; and newer strategies involving CLDN18.2, FGFR2b, and tumor-agnostic alterations such as NTRK fusions. The review also considers the predictive biomarkers used to guide treatment selection and the growing integration of systemic therapy with surgery in neoadjuvant, perioperative, adjuvant, and conversion settings. However, clinical efficacy alone does not determine whether new treatments become part of routine practice. Regulatory approval, reimbursement, access to molecular testing, and the availability of specialized multidisciplinary care are equally important. The rapidly evolving treatment landscape for GI cancers therefore requires clinical decisions that account for tumor biology, anatomical resectability, molecular eligibility, expected benefit, treatment-related toxicity, and local access to therapy. Expanding access to comprehensive biomarker testing and effective molecularly guided treatments will be essential to translate progress in precision oncology into more personalized and equitable care for patients with GI cancers.<\/jats:p>","DOI":"10.3390\/cancers18162675","type":"journal-article","created":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T13:11:57Z","timestamp":1787058717000},"page":"2675","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Biological and Targeted Therapies in the Multidisciplinary Management of Gastrointestinal Cancers"],"prefix":"10.3390","volume":"18","author":[{"given":"Marek","family":"Kos","sequence":"first","affiliation":[{"name":"Department of Epidemiology, Institute of Rural Health, 20-090 Lublin, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krzysztof","family":"Bojarski","sequence":"additional","affiliation":[{"name":"General Surgery Department, Independent Public Health Care Facility in \u0141\u0119czna (SP ZOZ in \u0141\u0119czna), 21-010 \u0141\u0119czna, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Milena","family":"Czosnek","sequence":"additional","affiliation":[{"name":"Department of Experimental Immunology, Medical University of Lublin, 20-093 Lublin, Poland"},{"name":"Student Research Group of Experimental Immunology, Medical University of Lublin, 20-093 Lublin, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4979-2726","authenticated-orcid":false,"given":"Jan","family":"\u015anie\u017cy\u0144ski","sequence":"additional","affiliation":[{"name":"Doctoral School of the Medical University of Lublin, Medical University of Lublin, 20-093 Lublin, Poland"},{"name":"II Clinic of General, Gastroenterological and Digestive System Cancer Surgery, University Clinical Hospital No. 1, 20-081 Lublin, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bartosz","family":"Wilczy\u0144ski","sequence":"additional","affiliation":[{"name":"Doctoral School of the Medical University of Lublin, Medical University of Lublin, 20-093 Lublin, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9530-6659","authenticated-orcid":false,"given":"Paulina","family":"Mertowska","sequence":"additional","affiliation":[{"name":"Department of Experimental Immunology, Medical University of Lublin, 20-093 Lublin, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ewelina","family":"Grywalska","sequence":"additional","affiliation":[{"name":"Department of Experimental Immunology, Medical University of Lublin, 20-093 Lublin, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7121-1396","authenticated-orcid":false,"given":"Sebastian","family":"Mertowski","sequence":"additional","affiliation":[{"name":"Department of Experimental Immunology, Medical University of Lublin, 20-093 Lublin, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,8,18]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"Vishwanath, A., Krishna, S., Manudhane, A.P., Hart, P.A., and Krishna, S.G. (2024). Early-Onset Gastrointestinal Malignancies: An Investigation into a Rising Concern. Cancers, 16.","DOI":"10.20944\/preprints202403.0720.v1"},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"Jiang, J., Xie, Z., Wang, Q., Wang, B., Huang, R., Xu, W., Shang, C., and Chen, Y. (2025). Epidemiological Trends in Gastrointestinal Cancers and Risk Factors across U.S. States from 2000 to 2021: A Systematic Analysis for the Global Burden of Disease Study 2021. BMC Public Health, 25.","DOI":"10.1186\/s12889-024-21192-3"},{"key":"ref_3","first-page":"236","article-title":"Global Burden of Five Major Types of Gastrointestinal Cancer","volume":"19","author":"Singh","year":"2024","journal-title":"Prz. Gastroenterol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"e70245","DOI":"10.1002\/cncr.70245","article-title":"Gastrointestinal Cancer Statistics in 2022 and Projection to 2050: GLOBOCAN Estimates across 185 Countries","volume":"132","author":"Danpanichkul","year":"2026","journal-title":"Cancer"},{"key":"ref_5","unstructured":"(2026, June 16). Global Burden of Gastrointestinal Cancers. Available online: https:\/\/gco.iarc.fr\/stories\/gastro-intestinal\/en."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"44","DOI":"10.21147\/j.issn.1000-9604.2023.01.05","article-title":"Nonoperative Management of Gastrointestinal Malignancies in Era of Neoadjuvant Treatment","volume":"35","author":"Chen","year":"2023","journal-title":"Chin. J. Cancer Res."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1038\/s41392-024-02097-4","article-title":"Digestive Cancers: Mechanisms, Therapeutics and Management","volume":"10","author":"Zhan","year":"2025","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Mela, E., and Frountzas, M. (2025). Gastrointestinal Cancer: Outcomes and Therapeutic Management. J. Clin. Med., 14.","DOI":"10.3390\/jcm14217541"},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Brlek, P., \u0160karo, V., Hrvatin, N., Buli\u0107, L., Petrovi\u0107, A., Proji\u0107, P., Smoli\u0107, M., Shah, P., and Primorac, D. (2025). Advances in Precision Oncology: From Molecular Profiling to Regulatory-Approved Targeted Therapies. Cancers, 17.","DOI":"10.3390\/cancers17213500"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.1016\/j.cell.2024.02.041","article-title":"Cancer Biomarkers-Emerging Trends and Clinical Implications for Personalized Treatment","volume":"187","author":"Passaro","year":"2024","journal-title":"Cell"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1186\/s43556-025-00361-9","article-title":"Gastrointestinal Cancer: Molecular Pathogenesis and Targeted Therapy","volume":"6","author":"Jin","year":"2025","journal-title":"Mol. Biomed."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"103038","DOI":"10.1016\/j.ctrv.2025.103038","article-title":"Precision Oncology in Gastric Cancer: Shaping the Future of Personalized Treatment","volume":"141","author":"Migliore","year":"2025","journal-title":"Cancer Treat. Rev."},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Wu, S., and Thawani, R. (2025). Tumor-Agnostic Therapies in Practice: Challenges, Innovations, and Future Perspectives. Cancers, 17.","DOI":"10.3390\/cancers17050801"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/s41073-019-0064-8","article-title":"SANRA\u2014A Scale for the Quality Assessment of Narrative Review Articles","volume":"4","author":"Baethge","year":"2019","journal-title":"Res. Integr. Peer Rev."},{"key":"ref_15","unstructured":"U.S. Food and Drug Administration (2026, June 16). About FDA, Available online: https:\/\/www.fda.gov\/about-fda."},{"key":"ref_16","unstructured":"(2026, June 16). European Medicines Agency (EMA). Available online: https:\/\/www.ema.europa.eu\/en\/homepage."},{"key":"ref_17","unstructured":"(2026, June 16). Refundacja-Ministerstwo Zdrowia-Portal Gov.pl, Available online: https:\/\/www.gov.pl\/web\/zdrowie\/refundacja3."},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Rosa, F., Schena, C.A., Laterza, V., Quero, G., Fiorillo, C., Strippoli, A., Pozzo, C., Papa, V., and Alfieri, S. (2022). The Role of Surgery in the Management of Gastric Cancer: State of the Art. Cancers, 14.","DOI":"10.3390\/cancers14225542"},{"key":"ref_19","unstructured":"ESMO (2026, June 16). Clinical Practice Guidelines: Gastrointestinal Cancers|ESMO. Available online: https:\/\/www.esmo.org\/guidelines\/esmo-clinical-practice-guidelines-gastrointestinal-cancers."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"103041","DOI":"10.1016\/j.ctrv.2025.103041","article-title":"Evolving Treatment Strategies for Resectable Gastric Cancer: Bridging Asia-West Disparities toward Personalized and Integrated Therapy","volume":"141","author":"Zhao","year":"2025","journal-title":"Cancer Treat. Rev."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"53","DOI":"10.5604\/01.3001.0015.8793","article-title":"Polish Consensus on Gastric Cancer Diagnosis and Treatment-Update 2022","volume":"94","author":"Richter","year":"2022","journal-title":"Pol. Przegl Chir."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1097\/ot9.0000000000000009","article-title":"Review of Surgical Strategies in Gastric Cancer","volume":"9","author":"Vyas","year":"2023","journal-title":"Oncol. Transl. Med."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"oyaf020","DOI":"10.1093\/oncolo\/oyaf020","article-title":"Select Updates from ASCO and ESMO 2024 for Gastrointestinal Cancer Care","volume":"30","author":"Jang","year":"2025","journal-title":"Oncologist"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1002\/jso.26924","article-title":"Lymphadenectomy and Margin-Negative Resection for Biliary Tract Cancer Surgery in the United States-Differential Technical Performance by Approach","volume":"126","author":"Kim","year":"2022","journal-title":"J. Surg. Oncol."},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"P\u00e9rez-Santiago, L., Huntley Pascual, D., S\u00e1nchez Lara, J.S., Huerta, M., and Dorcaratto, D. (2026). How to Integrate Surgery into the Multidisciplinary Treatment of Liver-Only Metastatic Colorectal Cancer. Cancers, 18.","DOI":"10.3390\/cancers18030489"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"100231","DOI":"10.1016\/j.esmogo.2025.100231","article-title":"Lymph Node Mapping-Based Optimal Bowel-Resection Margin and Central Radicality in Colon Cancer Surgery: An International, Prospective, Observational Cohort Study","volume":"9","author":"Ueno","year":"2025","journal-title":"ESMO Gastrointest. Oncol."},{"key":"ref_27","first-page":"1","article-title":"The Evolving Role of Esophageal Surgery\u2013Advancements, Challenges, and the Path Forward","volume":"10","author":"Chevallay","year":"2025","journal-title":"Innov. Surg. Sci."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"251","DOI":"10.21037\/jtd-2025-aw-2175","article-title":"Optimizing Perioperative Care in Esophagectomy: A Narrative Review","volume":"18","author":"Geraedts","year":"2026","journal-title":"J. Thorac. Dis."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"3358","DOI":"10.3748\/wjg.v16.i27.3358","article-title":"R0 Resection in the Treatment of Gastric Cancer: Room for Improvement","volume":"16","author":"Biondi","year":"2010","journal-title":"World J. Gastroenterol."},{"key":"ref_30","unstructured":"ESMO (2026, June 16). Living Guideline: Gastric Cancer|ESMO. Available online: https:\/\/www.esmo.org\/guidelines\/living-guidelines\/esmo-living-guideline-gastric-cancer."},{"key":"ref_31","unstructured":"ESMO (2026, June 16). Clinical Practice Guideline: Pancreatic Cancer|ESMO. Available online: https:\/\/www.esmo.org\/guidelines\/esmo-clinical-practice-guideline-pancreatic-cancer."},{"key":"ref_32","doi-asserted-by":"crossref","unstructured":"Noel, C., Azeez, A., Du Preez, A., and Noel, K. (2025). Arterial Resections in Pancreatic Cancer\u2014An Updated Systematic Review and Meta-Analysis. Cancers, 17.","DOI":"10.3390\/cancers17091540"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"48","DOI":"10.21037\/cco-21-39","article-title":"Do Arterial Resections Improve Survival in Pancreatic Cancer?\u2014A Narrative Review","volume":"10","author":"Rebelo","year":"2021","journal-title":"Chin. Clin. Oncol."},{"key":"ref_34","doi-asserted-by":"crossref","unstructured":"Pelegr\u00edn-Mateo, F.J., and Gallego Plazas, J. (2025). Integration of Radical Intent Treatment in Colorectal Liver Metastases. Onco, 5.","DOI":"10.3390\/onco5040045"},{"key":"ref_35","doi-asserted-by":"crossref","unstructured":"Rodr\u00edguez, M.R., Biedma, B.A., Rodr\u00edguez P\u00e9rez, I., and Romeo, J.A. (2025). Elucidating the Role of KRAS, NRAS, and BRAF Mutations and Microsatellite Instability in Colorectal Cancer via Next-Generation Sequencing. Cancers, 17.","DOI":"10.3390\/cancers17132071"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1038\/s41392-024-01953-7","article-title":"Signaling Pathways Involved in Colorectal Cancer: Pathogenesis and Targeted Therapy","volume":"9","author":"Li","year":"2024","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_37","unstructured":"ESMO (2026, June 16). Clinical Practice Guideline: Localised Rectal Cancer|ESMO. Available online: https:\/\/www.esmo.org\/guidelines\/esmo-clinical-practice-guideline-localised-rectal-cancer."},{"key":"ref_38","unstructured":"ESMO (2026, June 16). Clinical Practice Guideline: Hepatocellular Carcinoma|ESMO. Available online: https:\/\/www.esmo.org\/guidelines\/esmo-clinical-practice-guideline-hepatocellular-carcinoma."},{"key":"ref_39","doi-asserted-by":"crossref","unstructured":"Morishita, A., Oura, K., Tai, H., Yano, R., Nakahara, M., Tadokoro, T., Fujita, K., Mimura, S., Tani, J., and Tatsuta, M. (2026). Advances in the Therapeutic Landscape of Hepatocellular Carcinoma: Current Strategies and Future Perspectives. Cancers, 18.","DOI":"10.3390\/cancers18040609"},{"key":"ref_40","unstructured":"ESMO (2026, June 16). Clinical Practice Guideline: Biliary Tract Cancer|ESMO. Available online: https:\/\/www.esmo.org\/guidelines\/esmo-clinical-practice-guideline-biliary-tract-cancer."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"e0743","DOI":"10.1097\/HC9.0000000000000743","article-title":"Intrahepatic Cholangiocarcinoma: Insights on Molecular Testing, Targeted Therapies, and Future Directions from a Multidisciplinary Panel","volume":"9","author":"Gujarathi","year":"2025","journal-title":"Hepatol. Commun."},{"key":"ref_42","doi-asserted-by":"crossref","unstructured":"Cillis, J., Chen, C., Deshpande, S., Fong, Y., and Chaurasiya, S. (2026). Current Status of Drug Treatment of Cholangiocarcinoma\u2014Updated Progress and Critical Limitations. Pharmaceuticals, 19.","DOI":"10.3390\/ph19040554"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1038\/s41575-025-01153-w","article-title":"Cholangiocarcinoma 2026: Status Quo, Unmet Needs and Priorities","volume":"23","author":"Banales","year":"2026","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"ref_44","doi-asserted-by":"crossref","unstructured":"Giercuszkiewicz-Ha\u015bnik, K., Morak-M\u0142odawska, B., and Jele\u0144, M. (2026). Molecularly Targeted Therapies in Oncology: Mechanisms, Resistance, and Combination Strategies. Molecules, 31.","DOI":"10.3390\/molecules31071195"},{"key":"ref_45","doi-asserted-by":"crossref","unstructured":"Satala, C.-B., Gur\u0103u, G., Patrichi, G., Gurau, A.-M., Mehedinti, R.-C., Leibovici, A.R., and Mihalache, D. (2026). FGFR2b in Gastric Cancer: Translating a Therapeutic Target into a Reliable Biomarker. Cancers, 18.","DOI":"10.3390\/cancers18121863"},{"key":"ref_46","first-page":"167","article-title":"Immunotherapy in Gastrointestinal Cancers: Current Insights","volume":"17","author":"Jiang","year":"2025","journal-title":"Clin. Pharmacol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"e70412","DOI":"10.1002\/mco2.70412","article-title":"The Role of Immune Checkpoint Inhibitors in Cancer Therapy: Mechanism and Therapeutic Advances","volume":"6","author":"Chen","year":"2025","journal-title":"MedComm"},{"key":"ref_48","doi-asserted-by":"crossref","unstructured":"Sobhani, N., Tardiel-Cyril, D.R., Davtyan, A., Generali, D., Roudi, R., and Li, Y. (2021). CTLA-4 in Regulatory T Cells for Cancer Immunotherapy. Cancers, 13.","DOI":"10.20944\/preprints202102.0150.v1"},{"key":"ref_49","doi-asserted-by":"crossref","unstructured":"Park, J., and Sk\u00e5lhegg, B.S. (2025). Combination of PD-1\/PD-L1 and CTLA-4 Inhibitors in the Treatment of Cancer\u2014A Brief Update. Front. Immunol., 16.","DOI":"10.3389\/fimmu.2025.1680838"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"e71749","DOI":"10.1002\/hsr2.71749","article-title":"Anti-PD-1\/PD-L1 Immunotherapy as a Potential Treatment Option for Lung Cancer: A Perspective Analysis of Opportunities and Challenges","volume":"9","author":"Mohiuddin","year":"2026","journal-title":"Health Sci. Rep."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"ltaf008","DOI":"10.1093\/immadv\/ltaf008","article-title":"CTLA-4\u2014Two Pathways to Anti-Tumour Immunity?","volume":"5","author":"Ward","year":"2025","journal-title":"Immunother. Adv."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"e517652","DOI":"10.1200\/EDBK-26-517652","article-title":"Translating Innovation Into Practice: Dissemination of Immune Checkpoint Inhibitors and Their Toxicity Management Across the Globe","volume":"46","author":"Trikha","year":"2026","journal-title":"Am. Soc. Clin. Oncol. Educ. Book."},{"key":"ref_53","doi-asserted-by":"crossref","unstructured":"Sharma, A., Kumar, H., Paladiya, R., Sisodia, R., Bharadwaj, H.R., Mohamed, I., Alsakarneh, S., Hayat, U., Sonaiya, S., and Pinnam, H.S. (2026). Antibody\u2013Drug Conjugates in Gastrointestinal Oncology: Clinical Efficacy and Inpatient Toxicity Management. J. Pers. Med., 16.","DOI":"10.3390\/jpm16040195"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"100154","DOI":"10.1016\/j.esmogo.2025.100154","article-title":"Expanding the Potential of Antibody\u2013Drug Conjugates in Gastrointestinal Malignancies: Beyond HER2 Targets","volume":"8","author":"Ntellas","year":"2025","journal-title":"ESMO Gastrointest. Oncol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"4680","DOI":"10.1158\/1078-0432.CCR-21-0557","article-title":"FDA Approval Summary: Pembrolizumab for the First-Line Treatment of Patients with MSI-H\/dMMR Advanced Unresectable or Metastatic Colorectal Carcinoma","volume":"27","author":"Casak","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"ref_56","doi-asserted-by":"crossref","unstructured":"Mulet-Margalef, N., Linares, J., Badia-Ramentol, J., Jimeno, M., Sanz Monte, C., Manzano Mozo, J.L., and Calon, A. (2023). Challenges and Therapeutic Opportunities in the dMMR\/MSI-H Colorectal Cancer Landscape. Cancers, 15.","DOI":"10.3390\/cancers15041022"},{"key":"ref_57","doi-asserted-by":"crossref","unstructured":"Koustas, E., Trifylli, E.-M., Oraiopoulos, V., Karamouzis, M.V., and Sarantis, P. (2026). Microsatellite Phenotype as a Guide for Immunotherapy in Colorectal Cancer: Current Status and Future Perspectives. Genes., 17.","DOI":"10.3390\/genes17060674"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"104775","DOI":"10.1016\/j.critrevonc.2025.104775","article-title":"Immunotherapy in Microsatellite-Stable Colorectal Cancer: Strategies to Overcome Resistance","volume":"212","author":"Chen","year":"2025","journal-title":"Crit. Rev. Oncol.\/Hematol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"3160","DOI":"10.3390\/curroncol29050257","article-title":"Current Role of Immunotherapy in Gastric, Esophageal and Gastro-Esophageal Junction Cancers\u2014A Report from the Western Canadian Gastrointestinal Cancer Consensus Conference","volume":"29","author":"Mulder","year":"2022","journal-title":"Curr. Oncol."},{"key":"ref_60","doi-asserted-by":"crossref","unstructured":"Peshin, S., Takrori, E., Kodali, N.A., Bashir, F., Gibson, M., and Singal, S. (2025). Therapeutic Frontiers in Gastroesophageal Cancer: Contemporary Concepts in Management and Therapy. Int. J. Mol. Sci., 26.","DOI":"10.3390\/ijms262311424"},{"key":"ref_61","first-page":"175","article-title":"The Role of Immunotherapy in Esophageal and Gastric Cancer","volume":"22","author":"Dedecker","year":"2023","journal-title":"Clin. Colorectal Cancer"},{"key":"ref_62","doi-asserted-by":"crossref","unstructured":"Narita, Y., and Muro, K. (2023). Updated Immunotherapy for Gastric Cancer. J. Clin. Med., 12.","DOI":"10.3390\/jcm12072636"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"111","DOI":"10.54254\/2753-8818\/2025.19705","article-title":"Combined Treatment of HCC with CTLA-4 Inhibitors and PD-1\/PD-L1 Inhibitors: Mechanisms, Progress and Challenges","volume":"69","author":"Wang","year":"2025","journal-title":"Theor. Nat. Sci."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1186\/s13045-025-01739-6","article-title":"Combination Immunotherapy in Hepatocellular Carcinoma: Synergies among Immune Checkpoints, TKIs, and Chemotherapy","volume":"18","author":"Dai","year":"2025","journal-title":"J. Hematol. Oncol."},{"key":"ref_65","doi-asserted-by":"crossref","unstructured":"Peshin, S., Bashir, F., Kodali, N.A., Dharia, A., Zaiter, S., Singal, S., and Moka, N. (2025). Immunotherapy in GI Cancers: Lessons from Key Trials and Future Clinical Applications. Antibodies, 14.","DOI":"10.3390\/antib14030058"},{"key":"ref_66","doi-asserted-by":"crossref","unstructured":"Laface, C., Memeo, R., Maselli, F.M., Santoro, A.N., Iaia, M.L., Ambrogio, F., Laterza, M., Cazzato, G., Guarini, C., and De Santis, P. (2023). Immunotherapy and Pancreatic Cancer: A Lost Challenge?. Life, 13.","DOI":"10.3390\/life13071482"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"e70416","DOI":"10.1002\/cncr.70416","article-title":"Integrating Antibody\u2013Drug Conjugates into Solid Tumor Oncology: Current Standards and Future Directions","volume":"132","author":"Mansinho","year":"2026","journal-title":"Cancer"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"3185","DOI":"10.32604\/or.2025.065818","article-title":"Immune Checkpoint Inhibitors in Gastrointestinal Cancers: Current Evidence and Future Directions","volume":"33","author":"Toyozumi","year":"2025","journal-title":"Oncol. Res."},{"key":"ref_69","doi-asserted-by":"crossref","unstructured":"Ratti, M., Citterio, C., Orlandi, E., Vecchia, S., Anselmi, E., Toscani, I., Rotolo, M., Salati, M., and Ghidini, M. (2025). Fighting HER2 in Gastric Cancer: Current Approaches and Future Landscapes. Int. J. Mol. Sci., 26.","DOI":"10.3390\/ijms26157285"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"852748","DOI":"10.1155\/2014\/852748","article-title":"Human Epidermal Growth Factor Receptor 2 (HER2) in Cancers: Overexpression and Therapeutic Implications","volume":"2014","author":"Iqbal","year":"2014","journal-title":"Mol. Biol. Int."},{"key":"ref_71","doi-asserted-by":"crossref","unstructured":"Wang, H. (2025). The Role of HER2 in Cancer: Molecular Mechanisms, Clinical Impact, and Advances in Targeted Therapies. Role of HER2\u2014From Molecular Mechanisms to Targeted Therapies, IntechOpen.","DOI":"10.5772\/intechopen.1008919"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"102789","DOI":"10.1016\/j.ctrv.2024.102789","article-title":"HER-2 Directed Therapies across Gastrointestinal Tract Cancers\u2014A New Frontier","volume":"129","author":"Jones","year":"2024","journal-title":"Cancer Treat. Rev."},{"key":"ref_73","doi-asserted-by":"crossref","unstructured":"(2024). Evaluation of HER2 Immunohistochemistry-Positive and Immunohistochemistry-Negative FISH Amplification Breast Cancers Using next-Generation Sequencing. Oncologie, 26, 861\u2013866.","DOI":"10.1515\/oncologie-2024-0271"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"4619","DOI":"10.3748\/wjg.v22.i19.4619","article-title":"HER2 Testing in Gastric Cancer: An Update","volume":"22","year":"2016","journal-title":"World J. Gastroenterol."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"5879","DOI":"10.3748\/wjg.v22.i26.5879","article-title":"HER2 Heterogeneity in Gastric\/Gastroesophageal Cancers: From Benchside to Practice","volume":"22","author":"Grillo","year":"2016","journal-title":"World J. Gastroenterol."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"519498","DOI":"10.1155\/2010\/519498","article-title":"HER2 Expression in Gastric Cancer: Rare, Heterogeneous and of No Prognostic Value\u2014Conclusions from 924 Cases of Two Independent Series","volume":"32","author":"Grabsch","year":"2010","journal-title":"Anal. Cell. Pathol."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1080\/13543784.2017.1315406","article-title":"Perspectives of HER2-Targeting in Gastric and Esophageal Cancer","volume":"26","author":"Gerson","year":"2017","journal-title":"Expert. Opin. Investig. Drugs"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"279","DOI":"10.5603\/ocp.106480","article-title":"Anti-HER2 Treatment in Solid Tumors beyond Breast Cancer with HER2 Overexpression\u2014An Exciting New Remake of the Old Target","volume":"21","author":"Semeradt","year":"2025","journal-title":"Oncol. Clin. Pract."},{"key":"ref_79","doi-asserted-by":"crossref","unstructured":"Pous, A., Notario, L., Hierro, C., Layos, L., and Bug\u00e9s, C. (2023). HER2-Positive Gastric Cancer: The Role of Immunotherapy and Novel Therapeutic Strategies. Int. J. Mol. Sci., 24.","DOI":"10.20944\/preprints202306.0932.v1"},{"key":"ref_80","doi-asserted-by":"crossref","unstructured":"Hussain, A., Iqbal, Q., Isaac, S., Shariff, F., Tariq, E., Awais, H., Mainkar, N., Reis, H.L., Arora, A., and Deotare, A. (2025). Efficacy and Safety of Trastuzumab Deruxtecan in Gastrointestinal Malignancies: A Systemic Review and Meta-Analysis. Front. Gastroenterol., 4.","DOI":"10.3389\/fgstr.2025.1559934"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1007\/s11523-023-00998-y","article-title":"Trastuzumab Deruxtecan: A Review in Gastric or Gastro-Oesophageal Junction Adenocarcinoma","volume":"18","author":"Kang","year":"2023","journal-title":"Target. Oncol."},{"key":"ref_82","unstructured":"EMA (2026, June 16). Enhertu (Trastuzumab Deruxtecan), MAH: Daiichi Sankyo Europe GmbH. Available online: https:\/\/ec.europa.eu\/newsroom\/ema\/items\/872112\/en."},{"key":"ref_83","unstructured":"Trastuzumab Deruxtecan (Enhertu) (2026, August 04). Indication: As Monotherapy, Is Indicated for the Treatment of Adult Patients with Unresectable, Locally Advanced or Metastatic HER2-Positive Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma Who Have Received a Prior Trastuzumab-Based Regimen: Reimbursement Recommendation, Available online: http:\/\/www.ncbi.nlm.nih.gov\/books\/NBK614929\/."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"25","DOI":"10.21037\/aoe-25-28","article-title":"Advancing Precision Oncology for Esophagogastric Cancer in the Era of Antibody-Drug Conjugates","volume":"8","author":"Mahmood","year":"2025","journal-title":"Ann. Esophagus"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1186\/s13045-025-01704-3","article-title":"Antibody\u2013Drug Conjugates (ADCs): Current and Future Biopharmaceuticals","volume":"18","author":"Wang","year":"2025","journal-title":"J. Hematol. Oncol."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1038\/s41420-025-02429-5","article-title":"Navigating the Future of Gastric Cancer Treatment: A Review on the Impact of Antibody-Drug Conjugates","volume":"11","author":"Yin","year":"2025","journal-title":"Cell Death Discov."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1186\/s40364-025-00779-x","article-title":"Decoding Tumor Angiogenesis: Pathways, Mechanisms, and Future Directions in Anti-Cancer Strategies","volume":"13","author":"Liu","year":"2025","journal-title":"Biomark. Res."},{"key":"ref_88","doi-asserted-by":"crossref","unstructured":"Li, J., Li, Z., and Wang, K. (2025). Targeting Angiogenesis in Gastrointestinal Tumors: Strategies from Vascular Disruption to Vascular Normalization and Promotion Strategies Angiogenesis Strategies in GI Tumor Therapy. Front. Immunol., 16.","DOI":"10.3389\/fimmu.2025.1550752"},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1097\/01.sla.0000075047.47175.35","article-title":"Clinical Significance of Angiogenesis in Gastrointestinal Cancers","volume":"238","author":"Poon","year":"2003","journal-title":"Ann. Surg."},{"key":"ref_90","doi-asserted-by":"crossref","unstructured":"Nghiem, E., Friedman, B., Srivastava, N., Takchi, A., Mohammadi, M., Dedushi, D., Edelmann, W., Kuang, C., and Bteich, F. (2025). Emerging Strategies for Targeting Angiogenesis and the Tumor Microenvironment in Gastrointestinal Malignancies: A Comprehensive Review. Pharmaceuticals, 18.","DOI":"10.3390\/ph18081160"},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"485","DOI":"10.21037\/jgo.2017.01.07","article-title":"Biological Agents in Gastrointestinal Cancers: Adverse Effects and Their Management","volume":"8","author":"Arora","year":"2017","journal-title":"J. Gastrointest. Oncol."},{"key":"ref_92","doi-asserted-by":"crossref","unstructured":"Saoudi Gonz\u00e1lez, N., Castet, F., \u00c9lez, E., Macarulla, T., and Tabernero, J. (2022). Current and Emerging Anti-Angiogenic Therapies in Gastrointestinal and Hepatobiliary Cancers. Front. Oncol., 12.","DOI":"10.3389\/fonc.2022.1021772"},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"105892","DOI":"10.1016\/j.esmoop.2025.105892","article-title":"Efficacy and Safety of Atezolizumab plus Bevacizumab in MSI-like Metastatic Colorectal Cancer: A Multicenter, Single-Arm, Phase II, Open-Label Clinical Trial","volume":"10","author":"Elez","year":"2025","journal-title":"ESMO Open"},{"key":"ref_94","doi-asserted-by":"crossref","unstructured":"Chen, M.-H., Lu, S.-N., Chen, C.-H., Lin, P.-C., Jiang, J.-K., D\u2019yachkova, Y., Lukanowski, M., Cheng, R., and Chen, L.-T. (2021). How May Ramucirumab Help Improve Treatment Outcome for Patients with Gastrointestinal Cancers?. Cancers, 13.","DOI":"10.3390\/cancers13143536"},{"key":"ref_95","unstructured":"Malhotra, U. (2026, June 16). Ramucirumab: A Novel Antiangiogenic Agent for Gastric Cancer and Gastroesophageal Junction Cancer|Targeted Oncology\u2014Immunotherapy, Biomarkers, and Cancer Pathways. Available online: https:\/\/www.targetedonc.com\/view\/ramucirumab-a-novel-antiangiogenic-agent-for-gastric-cancer-and-gastroesophageal-junction-cancer."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1177\/1756283X13502637","article-title":"Aflibercept in the Treatment of Patients with Metastatic Colorectal Cancer: Latest Findings and Interpretations","volume":"6","author":"Tang","year":"2013","journal-title":"Ther. Adv. Gastroenterol."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/s40487-013-0002-8","article-title":"Efficacy and Safety of Aflibercept and Its Role in the Treatment of Metastatic Colorectal Cancer","volume":"1","author":"Salem","year":"2013","journal-title":"Rare Cancers Ther."},{"key":"ref_98","doi-asserted-by":"crossref","unstructured":"Wee, P., and Wang, Z. (2017). Epidermal Growth Factor Receptor Cell Proliferation Signaling Pathways. Cancers, 9.","DOI":"10.3390\/cancers9050052"},{"key":"ref_99","doi-asserted-by":"crossref","unstructured":"Leite, L.F., Noronha, M.M., de Menezes, J.S.A., da Concei\u00e7\u00e3o, L.D., Almeida, L.F.C., Cappellaro, A.P., Belotto, M., Biachi de Castria, T., Peixoto, R.D., and Megid, T.B.C. (2025). Anti-EGFR Therapy in Metastatic Colorectal Cancer: Identifying, Tracking, and Overcoming Resistance. Cancers, 17.","DOI":"10.3390\/cancers17172804"},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"4131","DOI":"10.7150\/ijms.122194","article-title":"Real-World Safety of Anti-EGFR Antibodies: 20-Year Pharmacovigilance of Cetuximab and Panitumumab","volume":"22","author":"Jin","year":"2025","journal-title":"Int. J. Med. Sci."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"14476","DOI":"10.3390\/cimb46120869","article-title":"Limited Efficacy of Anti-EGFR Monoclonal Antibodies in Colorectal Cancer Patients with Rare RAS Variants: Analysis of the C-CAT Database","volume":"46","author":"Suzuki","year":"2024","journal-title":"Curr. Issues Mol. Biol."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"e05785","DOI":"10.1002\/advs.202505785","article-title":"EGFR: New Insights on Its Activation and Mutation in Tumor and Tumor Immunotherapy","volume":"12","author":"Gu","year":"2025","journal-title":"Adv. Sci."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1038\/s41392-025-02473-8","article-title":"Targeting KRAS Mutations: Orchestrating Cancer Evolution and Therapeutic Challenges","volume":"10","author":"Choucair","year":"2025","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"3980","DOI":"10.18632\/oncotarget.14012","article-title":"Mechanisms of Resistance to Anti-EGFR Therapy in Colorectal Cancer","volume":"8","author":"Zhao","year":"2016","journal-title":"Oncotarget"},{"key":"ref_105","unstructured":"Pratt, V.M., Scott, S.A., Pirmohamed, M., Esquivel, B., Kattman, B.L., and Malheiro, A.J. (2026, August 04). Panitumumab Therapy and RAS and BRAF Genotype, MINI Medical Genetics Summaries, Available online: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK564800\/."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1007\/s00292-021-00946-5","article-title":"BRAF Testing in Metastatic Colorectal Carcinoma and Novel, Chemotherapy-Free Therapeutic Options","volume":"42","author":"Hummel","year":"2021","journal-title":"Pathologe"},{"key":"ref_107","doi-asserted-by":"crossref","unstructured":"Doleschal, B., Petzer, A., and Rumpold, H. (2022). Current Concepts of Anti-EGFR Targeting in Metastatic Colorectal Cancer. Front. Oncol., 12.","DOI":"10.3389\/fonc.2022.1048166"},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"107775","DOI":"10.1016\/j.esmoop.2026.107775","article-title":"Anti-EGFR-Based Maintenance versus Stop and Go in Patients with Left-Sided, Non-MSI-H, RAS\/BRAF-Wt Metastatic Colorectal Cancer: Individual Patient Data Pooled Analysis","volume":"11","author":"Raimondi","year":"2026","journal-title":"ESMO Open"},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1038\/s41698-025-00892-y","article-title":"Multidimensional Differences of Right- and Left-Sided Colorectal Cancer and Their Impact on Targeted Therapies","volume":"9","author":"Pammer","year":"2025","journal-title":"npj Precis. Oncol."},{"key":"ref_110","doi-asserted-by":"crossref","unstructured":"Yamaoka, T., Ohba, M., and Ohmori, T. (2017). Molecular-Targeted Therapies for Epidermal Growth Factor Receptor and Its Resistance Mechanisms. Int. J. Mol. Sci., 18.","DOI":"10.3390\/ijms18112420"},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1038\/nrgastro.2016.52","article-title":"Overcoming Resistance to Anti-EGFR Therapy\u2014Where Do We Stand?","volume":"13","author":"Schirripa","year":"2016","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"ref_112","doi-asserted-by":"crossref","unstructured":"Miyamoto, Y., Suyama, K., and Baba, H. (2017). Recent Advances in Targeting the EGFR Signaling Pathway for the Treatment of Metastatic Colorectal Cancer. Int. J. Mol. Sci., 18.","DOI":"10.3390\/ijms18040752"},{"key":"ref_113","doi-asserted-by":"crossref","unstructured":"R\u00edos-Hoyo, A., Monzon\u00eds, X., Vidal, J., Linares, J., and Montagut, C. (2024). Unveiling Acquired Resistance to Anti-EGFR Therapies in Colorectal Cancer: A Long and Winding Road. Front. Pharmacol., 15.","DOI":"10.3389\/fphar.2024.1398419"},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1038\/nature10868","article-title":"Unresponsiveness of Colon Cancer to BRAF(V600E) Inhibition through Feedback Activation of EGFR","volume":"483","author":"Prahallad","year":"2012","journal-title":"Nature"},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1158\/2159-8290.CD-11-0341","article-title":"EGFR-Mediated Re-Activation of MAPK Signaling Contributes to Insensitivity of BRAF Mutant Colorectal Cancers to RAF Inhibition with Vemurafenib","volume":"2","author":"Corcoran","year":"2012","journal-title":"Cancer Discov."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1200\/JCO.20.02088","article-title":"Encorafenib Plus Cetuximab as a New Standard of Care for Previously Treated BRAF V600E-Mutant Metastatic Colorectal Cancer: Updated Survival Results and Subgroup Analyses from the BEACON Study","volume":"39","author":"Tabernero","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"1632","DOI":"10.1056\/NEJMoa1908075","article-title":"Encorafenib, Binimetinib, and Cetuximab in BRAF V600E-Mutated Colorectal Cancer","volume":"381","author":"Kopetz","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"2125","DOI":"10.1056\/NEJMoa2308795","article-title":"Sotorasib plus Panitumumab in Refractory Colorectal Cancer with Mutated KRAS G12C","volume":"389","author":"Fakih","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1158\/2159-8290.CD-20-0187","article-title":"EGFR Blockade Reverts Resistance to KRASG12C Inhibition in Colorectal Cancer","volume":"10","author":"Amodio","year":"2020","journal-title":"Cancer Discov."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1056\/NEJMoa2212419","article-title":"Adagrasib with or without Cetuximab in Colorectal Cancer with Mutated KRAS G12C","volume":"388","author":"Yaeger","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"ref_121","doi-asserted-by":"crossref","unstructured":"Dominguez Wiscovitch, A., Sanchez Mendez, R.J., and Chuy, J. (2025). CLDN18.2-Targeted Therapy in Gastrointestinal Cancers. Cancers, 17.","DOI":"10.3390\/cancers17233764"},{"key":"ref_122","doi-asserted-by":"crossref","unstructured":"Wang, C., Wang, Y., Chen, J., Wang, Y., Pang, C., Liang, C., Yuan, L., and Ma, Y. (2023). CLDN18.2 Expression and Its Impact on Prognosis and the Immune Microenvironment in Gastric Cancer. BMC Gastroenterol., 23.","DOI":"10.1186\/s12876-023-02924-y"},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"611187","DOI":"10.2147\/CMAR.S611187","article-title":"CLDN18.2-Directed Therapeutics in Gastric and Gastroesophageal Junction Adenocarcinoma: Biomarker Assessment, Expression Dynamics, and Treatment Sequencing","volume":"18","author":"Liu","year":"2026","journal-title":"Cancer Manag. Res."},{"key":"ref_124","doi-asserted-by":"crossref","unstructured":"Poniewierska-Baran, A., Plewa, P., \u017babicka, Z., and Pawlik, A. (2025). Claudin18.2 as a Promising Therapeutic Target in Gastric Cancer. Cells, 14.","DOI":"10.3390\/cells14161285"},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"113491","DOI":"10.1016\/j.isci.2025.113491","article-title":"Targeting Claudin18.2 for Cancer Theranostics: From Molecular Imaging to Precision Therapy","volume":"28","author":"Liu","year":"2025","journal-title":"iScience"},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1080\/14737140.2026.2615855","article-title":"Zolbetuximab as a Gastric Lineage-Directed Immunotherapy: Mechanistic Rationale and Translational Evidence in CLDN18.2-Positive Gastroesophageal Adenocarcinoma","volume":"26","author":"Egebjerg","year":"2026","journal-title":"Expert. Rev. Anticancer. Ther."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"100278","DOI":"10.1016\/j.esmogo.2025.100278","article-title":"Clinicopathologic Correlates of Claudin 18.2 Expression in Esophagogastric Cancer at Multiple Expression Levels","volume":"11","author":"Maeng","year":"2026","journal-title":"ESMO Gastrointest. Oncol."},{"key":"ref_128","doi-asserted-by":"crossref","unstructured":"Easaw, J.C., Lim, H.J., Karachiwala, H., Gill, S., Zhu, X., and Bateman, J. (2025). Zolbetuximab or Immunotherapy as the Initial Targeted Therapy in CLDN18.2-Positive, HER2-Negative Advanced Gastric Cancer: Weighing the Options. Curr. Oncol., 32.","DOI":"10.3390\/curroncol32110648"},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"106053","DOI":"10.1016\/j.esmoop.2025.106053","article-title":"Claudin 18.2 Expression in Gastroesophageal Adenocarcinoma: Biomarker Overlap and Association with Clinical Outcomes in a European Cohort","volume":"11","author":"Pazo","year":"2026","journal-title":"ESMO Open"},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.2147\/OTT.S282718","article-title":"Targeting FGFR2 Positive Gastroesophageal Cancer: Current and Clinical Developments","volume":"15","author":"Gordon","year":"2022","journal-title":"Onco Targets Ther."},{"key":"ref_131","doi-asserted-by":"crossref","unstructured":"He, Z., Chen, Y., Li, G., Wang, J., Wang, Y., Tu, P., Huang, Y., Zhao, L., Pan, X., and Liu, H. (2026). FGFR Aberrations in Solid Tumors: Mechanistic Insights and Clinical Translation of Targeted Therapies. Cancers, 18.","DOI":"10.3390\/cancers18010089"},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"107698","DOI":"10.1016\/j.esmoop.2026.107698","article-title":"Global Prevalence of FGFR2b Protein Overexpression in Advanced Gastric Cancer and Gastroesophageal Junction Cancers: Pooled Analysis of Two Bemarituzumab Phase III Studies","volume":"11","author":"Maron","year":"2026","journal-title":"ESMO Open"},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"1981202","DOI":"10.1080\/19420862.2021.1981202","article-title":"Preclinical Characterization of Bemarituzumab, an Anti-FGFR2b Antibody for the Treatment of Cancer","volume":"13","author":"Xiang","year":"2021","journal-title":"MAbs"},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1007\/s12029-025-01214-y","article-title":"FGFR as a Predictive Marker for Targeted Therapy in Gastrointestinal Malignancies: A Systematic Review","volume":"56","author":"Seraji","year":"2025","journal-title":"J. Gastrointest. Cancer"},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"4305","DOI":"10.3390\/curroncol31080321","article-title":"Deciphering the FGFR2 Code: Innovative Targets in Gastric Cancer Therapy","volume":"31","author":"Tojjari","year":"2024","journal-title":"Curr. Oncol."},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1158\/2159-8290.CD-16-1000","article-title":"Polyclonal Secondary FGFR2 Mutations Drive Acquired Resistance to FGFR Inhibition in Patients with FGFR2 Fusion\u2013Positive Cholangiocarcinoma","volume":"7","author":"Goyal","year":"2017","journal-title":"Cancer Discov."},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1158\/1078-0432.CCR-23-1317","article-title":"Landscape of Clinical Resistance Mechanisms to FGFR Inhibitors in FGFR2-Altered Cholangiocarcinoma","volume":"30","author":"Wu","year":"2024","journal-title":"Clin. Cancer Res."},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1016\/j.jhep.2023.10.041","article-title":"Convergent MAPK Pathway Alterations Mediate Acquired Resistance to FGFR Inhibitors in FGFR2 Fusion-Positive Cholangiocarcinoma","volume":"80","author":"DiPeri","year":"2024","journal-title":"J. Hepatol."},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1056\/NEJMoa1903387","article-title":"Maintenance Olaparib for Germline BRCA-Mutated Metastatic Pancreatic Cancer","volume":"381","author":"Golan","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1016\/S1470-2045(20)30157-1","article-title":"Ivosidenib in IDH1-Mutant, Chemotherapy-Refractory Cholangiocarcinoma (ClarIDHy): A Multicentre, Randomised, Double-Blind, Placebo-Controlled, Phase 3 Study","volume":"21","author":"Macarulla","year":"2020","journal-title":"Lancet Oncol."},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.annonc.2022.10.506","article-title":"Biliary Tract Cancer: ESMO Clinical Practice Guideline for Diagnosis, Treatment and Follow-Up","volume":"34","author":"Vogel","year":"2023","journal-title":"Ann. Oncol."},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"1669","DOI":"10.1001\/jamaoncol.2021.3836","article-title":"Final Overall Survival Efficacy Results of Ivosidenib for Patients With Advanced Cholangiocarcinoma With IDH1 Mutation: The Phase 3 Randomized Clinical ClarIDHy Trial","volume":"7","author":"Zhu","year":"2021","journal-title":"JAMA Oncol."},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"101291","DOI":"10.1016\/j.drup.2025.101291","article-title":"Defining Homologous Recombination Deficiency Status in Pancreatic Ductal Adenocarcinoma: Clinical Implications for Evaluating Response to Platinum Chemotherapy","volume":"83","author":"Wang","year":"2025","journal-title":"Drug Resist. Updates"},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.1002\/ueg2.12773","article-title":"Homologous Repair-Deficient Pancreatic Cancer: Refined Targeting of DNA Damage Response Is an Effective Therapeutic Strategy","volume":"13","author":"Beutel","year":"2025","journal-title":"United Eur. Gastroenterol. J."},{"key":"ref_145","doi-asserted-by":"crossref","unstructured":"Principe, D.R. (2022). Precision Medicine for BRCA\/PALB2-Mutated Pancreatic Cancer and Emerging Strategies to Improve Therapeutic Responses to PARP Inhibition. Cancers, 14.","DOI":"10.3390\/cancers14040897"},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"2497","DOI":"10.1200\/JCO.21.00003","article-title":"Phase II Study of Maintenance Rucaparib in Patients With Platinum-Sensitive Advanced Pancreatic Cancer and a Pathogenic Germline or Somatic Variant in BRCA1, BRCA2, or PALB2","volume":"39","author":"Reiss","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1016\/S1470-2045(23)00242-5","article-title":"Zanidatamab for HER2-Amplified, Unresectable, Locally Advanced or Metastatic Biliary Tract Cancer (HERIZON-BTC-01): A Multicentre, Single-Arm, Phase 2b Study","volume":"24","author":"Harding","year":"2023","journal-title":"Lancet Oncol."},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1016\/S1470-2045(22)00541-1","article-title":"Tumour-Agnostic Efficacy and Safety of Selpercatinib in Patients with RET Fusion-Positive Solid Tumours Other than Lung or Thyroid Tumours (LIBRETTO-001): A Phase 1\/2, Open-Label, Basket Trial","volume":"23","author":"Subbiah","year":"2022","journal-title":"Lancet Oncol."},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1016\/S0140-6736(21)00153-7","article-title":"Biliary tract cancer","volume":"397","author":"Valle","year":"2021","journal-title":"Lancet"},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"e2500767","DOI":"10.1200\/PO-25-00767","article-title":"Living Guidelines for Tumor-Agnostic Therapies: A Pathway to Next-Generation Cancer Treatment","volume":"10","author":"Subbiah","year":"2026","journal-title":"JCO Precis. Oncol."},{"key":"ref_151","doi-asserted-by":"crossref","unstructured":"Gambardella, V., Tarazona, N., Cejalvo, J.M., Lombardi, P., Huerta, M., Rosell\u00f3, S., Fleitas, T., Roda, D., and Cervantes, A. (2020). Personalized Medicine: Recent Progress in Cancer Therapy. Cancers, 12.","DOI":"10.3390\/cancers12041009"},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"100084","DOI":"10.1016\/j.esmogo.2024.100084","article-title":"High Prevalence of NTRK Fusions in Sporadic dMMR\/MSI mCRC RAS\/RAF Wild-Type: An Opportunity for a Post-Immune Checkpoint Inhibitors Progression Rescue Strategy","volume":"5","author":"Svrcek","year":"2024","journal-title":"ESMO Gastrointest. Oncol."},{"key":"ref_153","doi-asserted-by":"crossref","unstructured":"Cataldi, C., Karao\u011flan, B.B., Liotta, E., and De Dosso, S. (2026). Decoding Immunotherapy Response in Colorectal Cancer: Translational Insights Beyond MSI. Cancers, 18.","DOI":"10.3390\/cancers18050852"},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"100341","DOI":"10.1016\/j.esmogo.2026.100341","article-title":"Checkpoint Inhibitors in Microsatellite Instability-High Metastatic Colorectal Cancer: Treatment Strategies, Specificities, and Care Management Questions","volume":"12","author":"Lonardi","year":"2026","journal-title":"ESMO Gastrointest. Oncol."},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1038\/s41392-021-00572-w","article-title":"Small Molecules in Targeted Cancer Therapy: Advances, Challenges, and Future Perspectives","volume":"6","author":"Zhong","year":"2021","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_156","doi-asserted-by":"crossref","first-page":"S26","DOI":"10.37765\/ajmc.2022.88845","article-title":"Comparative Effectiveness of Larotrectinib and Entrectinib for TRK Fusion Cancer","volume":"28","author":"Carlson","year":"2022","journal-title":"Am. J. Manag. Care"},{"key":"ref_157","doi-asserted-by":"crossref","first-page":"S370","DOI":"10.1016\/j.annonc.2022.04.431","article-title":"SO-32 Entrectinib in NTRK Fusion-Positive Gastrointestinal Cancers: Updated Integrated Analysis","volume":"33","author":"Lonardi","year":"2022","journal-title":"Ann. Oncol."},{"key":"ref_158","doi-asserted-by":"crossref","unstructured":"Sohn, S.-H., Sul, H.J., Kim, B.J., Kim, H.S., and Zang, D.Y. (2021). Entrectinib Induces Apoptosis and Inhibits the Epithelial-Mesenchymal Transition in Gastric Cancer with NTRK Overexpression. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms23010395"},{"key":"ref_159","doi-asserted-by":"crossref","first-page":"640","DOI":"10.3390\/ijtm4040045","article-title":"Tissue Biomarkers in Gastric Cancer Treatment: Present and Future","volume":"4","author":"Agnetti","year":"2024","journal-title":"Int. J. Transl. Med."},{"key":"ref_160","doi-asserted-by":"crossref","unstructured":"Palieri, R., De Luca, M., Balestra, F., Panzetta, G., Lotesoriere, C., Rizzi, F., Ricci, A.D., Mastrogiacomo, R., Curri, M.L., and Laghi, L.A. (2025). Liquid Biopsy in Gastrointestinal Oncology: Clinical Applications and Translational Integration of ctDNA, CTCs, and sEVs. Oncol. Rev., 19.","DOI":"10.3389\/or.2025.1702932"},{"key":"ref_161","doi-asserted-by":"crossref","first-page":"100465","DOI":"10.1016\/j.jlb.2026.100465","article-title":"Liquid Biopsies for the Diagnosis of Early-Stage Gastric Cancer: A 5-Year Systematic Review","volume":"12","author":"Papaioannou","year":"2026","journal-title":"J. Liq. Biopsy"},{"key":"ref_162","doi-asserted-by":"crossref","unstructured":"Njoku, V.C.E., Lee, Y., Ramesh, J., Kubatka, P., and B\u00fcsselberg, D. (2025). Precision Antibody Therapy in Gastric and Gastroesophageal Cancer: Targeting FGFR2b, CLDN18.2, and VEGFR2. Cells, 14.","DOI":"10.3390\/cells14211672"},{"key":"ref_163","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1038\/s41568-025-00824-9","article-title":"Acquired Resistance in Cancer: Towards Targeted Therapeutic Strategies","volume":"25","author":"Soragni","year":"2025","journal-title":"Nat. Rev. Cancer"},{"key":"ref_164","first-page":"305","article-title":"The Current State of Molecular Testing in the Treatment of Patients with Solid Tumors, 2019","volume":"69","author":"Goldberg","year":"2019","journal-title":"CA Cancer J. Clin."},{"key":"ref_165","doi-asserted-by":"crossref","unstructured":"Kendsersky, N.D., Erlick, M.R., Chen, E.Y., and Kennecke, H.F. (2026). The Evolving Role for Repeat Molecular Testing in Metastatic Colorectal Cancer. Cancers, 18.","DOI":"10.3390\/cancers18061007"},{"key":"ref_166","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1200\/JCO.23.00975","article-title":"Perioperative Atezolizumab Plus Fluorouracil, Leucovorin, Oxaliplatin, and Docetaxel for Resectable Esophagogastric Cancer: Interim Results from the Randomized, Multicenter, Phase II\/III DANTE Trial","volume":"42","author":"Lorenzen","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"ref_167","doi-asserted-by":"crossref","unstructured":"Semenova, Y., Kerimkulov, A., Uskenbayev, T., Zharlyganova, D., Shatkovskaya, O., Sarina, T., Manatova, A., Yessenbayeva, G., and Adylkhanov, T. (2025). Chemotherapy Options for Locally Advanced Gastric Cancer: A Review. Cancers, 17.","DOI":"10.3390\/cancers17050809"},{"key":"ref_168","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1002\/jso.26834","article-title":"Systemic Therapy for Gastric Cancer: Perioperative Strategies and Beyond","volume":"125","author":"Cann","year":"2022","journal-title":"J. Surg. Oncol."},{"key":"ref_169","doi-asserted-by":"crossref","first-page":"oyaf157","DOI":"10.1093\/oncolo\/oyaf157","article-title":"Efficacy of Perioperative and Neoadjuvant Therapies in Gastric and Gastroesophageal Junction Adenocarcinoma: A Network Meta-Analysis","volume":"30","author":"Anjum","year":"2025","journal-title":"Oncologist"},{"key":"ref_170","first-page":"e174054","article-title":"The Role of Surgery in the Multimodal Treatment of Gastrointestinal Stromal Tumors","volume":"8","author":"Dimitrov","year":"2026","journal-title":"Bulg. Soc. Med. Sci. J."},{"key":"ref_171","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1038\/s41591-023-02758-x","article-title":"Neoadjuvant Atezolizumab plus Chemotherapy in Gastric and Gastroesophageal Junction Adenocarcinoma: The Phase 2 PANDA Trial","volume":"30","author":"Verschoor","year":"2024","journal-title":"Nat. Med."},{"key":"ref_172","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/j.jtcvs.2024.06.020","article-title":"Perioperative Outcomes and Survival after Neoadjuvant Immunochemotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma","volume":"169","author":"Yang","year":"2025","journal-title":"J. Thorac. Cardiovasc. Surg."},{"key":"ref_173","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1016\/j.xjon.2023.03.015","article-title":"The Impact of Neoadjuvant Immunotherapy on Perioperative Outcomes and Survival after Esophagectomy for Esophageal Cancer","volume":"14","author":"Wong","year":"2023","journal-title":"JTCVS Open"},{"key":"ref_174","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1056\/NEJMoa2032125","article-title":"Adjuvant Nivolumab in Resected Esophageal or Gastroesophageal Junction Cancer","volume":"384","author":"Kelly","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_175","doi-asserted-by":"crossref","first-page":"2363","DOI":"10.1056\/NEJMoa2201445","article-title":"PD-1 Blockade in Mismatch Repair-Deficient, Locally Advanced Rectal Cancer","volume":"386","author":"Cercek","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_176","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.1056\/NEJMoa2400634","article-title":"Neoadjuvant Immunotherapy in Locally Advanced Mismatch Repair-Deficient Colon Cancer","volume":"390","author":"Chalabi","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"ref_177","doi-asserted-by":"crossref","first-page":"2038","DOI":"10.1016\/j.ejso.2021.02.019","article-title":"Conversion Therapy in Patients with Colorectal Liver Metastases","volume":"47","author":"Villard","year":"2021","journal-title":"Eur. J. Surg. Oncol."},{"key":"ref_178","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/S1470-2045(09)70330-4","article-title":"Tumour Response and Secondary Resectability of Colorectal Liver Metastases Following Neoadjuvant Chemotherapy with Cetuximab: The CELIM Randomised Phase 2 Trial","volume":"11","author":"Folprecht","year":"2010","journal-title":"Lancet Oncol."},{"key":"ref_179","doi-asserted-by":"crossref","unstructured":"Wang, D.-S., Ren, C., Li, S.-S., Fong, W.P., Wu, X.-J., Xiao, J., Li, B.-K., Zheng, Y., Ding, P.-R., and Chen, G. (2024). Cetuximab plus FOLFOXIRI versus Cetuximab plus FOLFOX as Conversion Regimen in RAS\/BRAF Wild-Type Patients with Initially Unresectable Colorectal Liver Metastases (TRICE Trial): A Randomized Controlled Trial. PLoS Med., 21.","DOI":"10.1371\/journal.pmed.1004389"},{"key":"ref_180","doi-asserted-by":"crossref","unstructured":"Anselmo, A., Cascone, C., Siragusa, L., Sensi, B., Materazzo, M., Riccetti, C., Bacchiocchi, G., Ielpo, B., Rosso, E., and Tisone, G. (2022). Disappearing Colorectal Liver Metastases: Do We Really Need a Ghostbuster?. Healthcare, 10.","DOI":"10.3390\/healthcare10101898"},{"key":"ref_181","first-page":"236","article-title":"The Tolerance of Gastrointestinal Organs to Stereotactic Body Radiation Therapy: What Do We Know so Far?","volume":"5","author":"Thomas","year":"2014","journal-title":"J. Gastrointest. Oncol."},{"key":"ref_182","doi-asserted-by":"crossref","first-page":"6721","DOI":"10.12998\/wjcc.v12.i34.6721","article-title":"Conversion Surgery after Gemcitabine and Cisplatin plus Durvalumab for Advanced Intrahepatic Cholangiocarcinoma: A Case Report","volume":"12","author":"Igata","year":"2024","journal-title":"World J. Clin. Cases"},{"key":"ref_183","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1007\/s00423-025-03630-x","article-title":"Survival Benefit of Conversion Surgery for Initially Unresectable Biliary Tract Cancer: A Systematic Review and Meta-Analysis","volume":"410","author":"Zhou","year":"2025","journal-title":"Langenbecks Arch. Surg."},{"key":"ref_184","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1111\/iwj.13139","article-title":"Impaired Wound Healing Secondary to Bevacizumab","volume":"16","author":"Ahn","year":"2019","journal-title":"Int. Wound J."},{"key":"ref_185","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1016\/j.cgh.2022.02.018","article-title":"UNOS Down-Staging Criteria for Liver Transplantation of Hepatocellular Carcinoma: Systematic Review and Meta-Analysis of 25 Studies","volume":"21","author":"Tan","year":"2023","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_186","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1007\/s13304-021-01089-1","article-title":"Conversion Surgery for Initially Unresectable Pancreatic Ductal Adenocarcinoma Following Induction Therapy: A Systematic Review of the Published Literature","volume":"74","author":"Zhou","year":"2022","journal-title":"Updates Surg."},{"key":"ref_187","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1007\/s13691-022-00545-y","article-title":"Conversion Surgery for Initially Unresectable Advanced Biliary Tract Cancer Treated with Gemcitabine plus Cisplatin Combination Chemotherapy: A Case Report and Literature Review","volume":"11","author":"Miyamoto","year":"2022","journal-title":"Int. Cancer Conf. J."},{"key":"ref_188","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1056\/NEJMoa2503701","article-title":"Perioperative Durvalumab in Gastric and Gastroesophageal Junction Cancer","volume":"393","author":"Janjigian","year":"2025","journal-title":"N. Engl. J. Med."},{"key":"ref_189","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1038\/sj.bjc.6605259","article-title":"Surgery with Curative-Intent in Patients Treated with First-Line Chemotherapy plus Bevacizumab for Metastatic Colorectal Cancer First BEAT and the Randomised Phase-III NO16966 Trial","volume":"101","author":"Okines","year":"2009","journal-title":"Br. J. Cancer"},{"key":"ref_190","doi-asserted-by":"crossref","unstructured":"Claasen, M.P.A.W., Sneiders, D., Rakk\u00e9, Y.S., Adam, R., Bhoori, S., Cillo, U., Fondevila, C., Reig, M., Sapisochin, G., and Tabrizian, P. (2023). European Society of Organ Transplantation (ESOT) Consensus Report on Downstaging, Bridging and Immunotherapy in Liver Transplantation for Hepatocellular Carcinoma. Transpl. Int., 36.","DOI":"10.3389\/ti.2023.11648"},{"key":"ref_191","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1007\/s12328-024-02014-w","article-title":"Successful Intrahepatic Cholangiocarcinoma Conversion Surgery after Administration of Fibroblast Growth Factor Receptor Inhibitor","volume":"17","author":"Kaneko","year":"2024","journal-title":"Clin. J. Gastroenterol."},{"key":"ref_192","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1002\/jso.20301","article-title":"Surgical Wound Healing Complications in Metastatic Colorectal Cancer Patients Treated with Bevacizumab","volume":"91","author":"Scappaticci","year":"2005","journal-title":"J. Surg. Oncol."},{"key":"ref_193","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1016\/j.ejso.2011.06.004","article-title":"Review: Incidence and Clinical Significance of Bevacizumab-Related Non-Surgical and Surgical Serious Adverse Events in Metastatic Colorectal Cancer","volume":"37","author":"Hompes","year":"2011","journal-title":"Eur. J. Surg. Oncol."},{"key":"ref_194","doi-asserted-by":"crossref","first-page":"177309","DOI":"10.1016\/j.ejphar.2025.177309","article-title":"Differences in Treatment Outcome between Translational Platforms in Developing Therapies for Gastrointestinal Cancers","volume":"991","author":"Pienkowski","year":"2025","journal-title":"Eur. J. Pharmacol."},{"key":"ref_195","doi-asserted-by":"crossref","first-page":"2027","DOI":"10.1080\/14796694.2025.2504246","article-title":"Biomarker Testing, Treatment Patterns and Outcomes in Previously Treated pMMR or Non-MSI-H Metastatic Colorectal Cancer Patients","volume":"21","author":"Desai","year":"2025","journal-title":"Future Oncol."},{"key":"ref_196","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1002\/cpt.1565","article-title":"A Comparison of EMA and FDA Decisions for New Drug Marketing Applications 2014\u20132016: Concordance, Discordance, and Why","volume":"107","author":"Kashoki","year":"2020","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_197","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1007\/s00210-025-04412-4","article-title":"Comparison of Drug Approvals of the FDA and EMA between 2013 and 2023","volume":"399","author":"Lau","year":"2026","journal-title":"Naunyn-Schmiedeberg\u2019s Arch. Pharmacol."},{"key":"ref_198","doi-asserted-by":"crossref","first-page":"jjaf111","DOI":"10.1093\/ecco-jcc\/jjaf111","article-title":"Comparison of the FDA and EMA Guidance on Drug Development in Ulcerative Colitis: An Expert Panel Review","volume":"19","author":"Vieujean","year":"2025","journal-title":"J. Crohns Colitis"},{"key":"ref_199","doi-asserted-by":"crossref","unstructured":"Mela, A., Poniatowski, \u0141.A., Drop, B., Furtak-Niczyporuk, M., Jaroszy\u0144ski, J., Wrona, W., Staniszewska, A., D\u0105browski, J., Czajka, A., and Jagielska, B. (2020). Overview and Analysis of the Cost of Drug Programs in Poland: Public Payer Expenditures and Coverage of Cancer and Non-Neoplastic Diseases Related Drug Therapies from 2015\u20132018 Years. Front. Pharmacol., 11.","DOI":"10.3389\/fphar.2020.01123"},{"key":"ref_200","doi-asserted-by":"crossref","first-page":"101555","DOI":"10.1016\/j.vhri.2025.101555","article-title":"Cost-Effectiveness of Pembrolizumab as First-Line Therapy for Advanced Colorectal Cancer With High Microsatellite Instability or Mismatched Repair Deficiency in Japan","volume":"54","author":"Taniguchi","year":"2026","journal-title":"Value Health Reg. Issues"},{"key":"ref_201","doi-asserted-by":"crossref","unstructured":"Xie, Y., Liu, Q., Xiao, S., Li, X., Qiu, L., and Gu, Y. (2025). Multinational Cost-Effectiveness Analysis of Pembrolizumab Combined with Chemotherapy as First-Line Treatment for Advanced Biliary Tract Cancer. Front. Public Health, 13.","DOI":"10.3389\/fpubh.2025.1597550"},{"key":"ref_202","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1186\/s13059-017-1215-1","article-title":"Multi-Omics Approaches to Disease","volume":"18","author":"Hasin","year":"2017","journal-title":"Genome Biol."},{"key":"ref_203","doi-asserted-by":"crossref","first-page":"1177932219899051","DOI":"10.1177\/1177932219899051","article-title":"Multi-Omics Data Integration, Interpretation, and Its Application","volume":"14","author":"Subramanian","year":"2020","journal-title":"Bioinform. Biol. Insights"},{"key":"ref_204","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1038\/s41571-024-00926-7","article-title":"Spatial Landscapes of Cancers: Insights and Opportunities","volume":"21","author":"Chen","year":"2024","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_205","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1158\/2159-8290.CD-21-0683","article-title":"Single-Cell Atlas of Lineage States, Tumor Microenvironment, and Subtype-Specific Expression Programs in Gastric Cancer","volume":"12","author":"Kumar","year":"2022","journal-title":"Cancer Discov."},{"key":"ref_206","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1038\/s41588-022-01088-x","article-title":"Single-Cell Analyses Define a Continuum of Cell State and Composition Changes in the Malignant Transformation of Polyps to Colorectal Cancer","volume":"54","author":"Becker","year":"2022","journal-title":"Nat. Genet."},{"key":"ref_207","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1038\/s41586-021-03634-9","article-title":"Exploring Tissue Architecture Using Spatial Transcriptomics","volume":"596","author":"Rao","year":"2021","journal-title":"Nature"},{"key":"ref_208","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1038\/nrc.2017.7","article-title":"Liquid Biopsies Come of Age: Towards Implementation of Circulating Tumour DNA","volume":"17","author":"Wan","year":"2017","journal-title":"Nat. Rev. Cancer"},{"key":"ref_209","unstructured":"Center for Drug Evaluation and Reasearch (2026, August 04). FDA Approves Pembrolizumab for Esophageal or GEJ Carcinoma. FDA 2021, Available online: https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-pembrolizumab-esophageal-or-gej-carcinoma."},{"key":"ref_210","unstructured":"(2026, August 04). Keytruda|European Medicines Agency (EMA). Available online: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/keytruda."},{"key":"ref_211","unstructured":"(2026, August 04). Obwieszczenie Ministra Zdrowia z Dnia 18 Grudnia 2025 r. w Sprawie Wykazu Refundowanych Lek\u00f3w, \u015arodk\u00f3w Spo\u017cywczych Specjalnego Przeznaczenia \u017bywieniowego Oraz Wyrob\u00f3w Medycznych na 1 Stycznia 2026 r.-Ministerstwo Zdrowia-Portal Gov.pl, Available online: https:\/\/www.gov.pl\/web\/zdrowie\/obwieszczenie-ministra-zdrowia-z-dnia-18-grudnia-2025-r-w-sprawie-wykazu-refundowanych-lekow-srodkow-spozywczych-specjalnego-przeznaczenia-zywieniowego-oraz-wyrobow-medycznych-na-1-stycznia-2026-r."},{"key":"ref_212","unstructured":"Center for Drug Evaluation and Reasearch (2026, August 04). FDA Approves Pembrolizumab with Chemotherapy for HER2-Negative Gastric or Gastroesophageal Junction Adenocarcinoma. FDA 2024, Available online: https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-pembrolizumab-chemotherapy-her2-negative-gastric-or-gastroesophageal-junction."},{"key":"ref_213","unstructured":"Center for Drug Evaluation and Reasearch (2026, August 04). FDA Approves Pembrolizumab for HER2 Positive Gastric or Gastroesophageal Junction Adenocarcinoma Expressing PD-L1 (CPS \u2265 1). FDA 2026, Available online: https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-pembrolizumab-her2-positive-gastric-or-gastroesophageal-junction-adenocarcinoma."},{"key":"ref_214","unstructured":"Center for Drug Evaluation and Reasearch (2026, August 04). FDA Approves Pembrolizumab with Chemotherapy for Biliary Tract Cancer. FDA 2024, Available online: https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-pembrolizumab-chemotherapy-biliary-tract-cancer."},{"key":"ref_215","unstructured":"Center for Drug Evaluation and Reasearch (2026, August 04). FDA Approves Pembrolizumab for First-Line Treatment of MSI-H\/dMMR Colorectal Cancer. FDA 2024, Available online: https:\/\/www.fda.gov\/drugs\/drug-approvals-and-databases\/fda-approves-pembrolizumab-first-line-treatment-msi-hdmmr-colorectal-cancer."},{"key":"ref_216","unstructured":"(2026, August 04). DailyMed-KEYTRUDA-Pembrolizumab Injection, Powder, Lyophilized, for Solution KEYTRUDA-Pembrolizumab Injection, Solution, Available online: https:\/\/dailymed.nlm.nih.gov\/dailymed\/drugInfo.cfm?setid=9333c79b-d487-4538-a9f0-71b91a02b287."},{"key":"ref_217","unstructured":"(2026, August 04). Search Orphan Drug Designations and Approvals, Available online: https:\/\/www.accessdata.fda.gov\/scripts\/opdlisting\/oopd\/detailedIndex.cfm?cfgridkey=545016."},{"key":"ref_218","unstructured":"(2026, August 04). Opdivo|European Medicines Agency (EMA). Available online: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/opdivo."},{"key":"ref_219","unstructured":"(2026, August 04). Search Orphan Drug Designations and Approvals, Available online: https:\/\/www.accessdata.fda.gov\/scripts\/opdlisting\/oopd\/detailedIndex.cfm?cfgridkey=531016."},{"key":"ref_220","unstructured":"Center for Drug Evaluation and Reasearch (2026, August 04). FDA Approves Nivolumab for Esophageal Squamous Cell Carcinoma. FDA 2024, Available online: https:\/\/www.fda.gov\/drugs\/drug-approvals-and-databases\/fda-approves-nivolumab-esophageal-squamous-cell-carcinoma."},{"key":"ref_221","unstructured":"Center for Drug Evaluation and Reasearch (2026, August 04). FDA Approves Nivolumab with Ipilimumab for Unresectable or Metastatic MSI-H or dMMR Colorectal Cancer. FDA 2025, Available online: https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-nivolumab-ipilimumab-unresectable-or-metastatic-msi-h-or-dmmr-colorectal-cancer."},{"key":"ref_222","unstructured":"Center for Drug Evaluation and Reasearch (2026, August 04). FDA Approves Nivolumab with Ipilimumab for Unresectable or Metastatic Hepatocellular Carcinoma. FDA 2025, Available online: https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-nivolumab-ipilimumab-unresectable-or-metastatic-hepatocellular-carcinoma."},{"key":"ref_223","unstructured":"(2026, August 04). Search Orphan Drug Designations and Approvals, Available online: https:\/\/www.accessdata.fda.gov\/scripts\/opdlisting\/oopd\/detailedIndex.cfm?cfgridkey=619317."},{"key":"ref_224","unstructured":"(2026, August 04). Tecentriq|European Medicines Agency (EMA). Available online: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/tecentriq."},{"key":"ref_225","unstructured":"(2026, August 04). Search Orphan Drug Designations and Approvals, Available online: https:\/\/www.accessdata.fda.gov\/scripts\/opdlisting\/oopd\/detailedIndex.cfm?cfgridkey=785220."},{"key":"ref_226","unstructured":"(2026, August 04). Imfinzi|European Medicines Agency (EMA). Available online: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/imfinzi."},{"key":"ref_227","unstructured":"(2026, August 04). DailyMed-IMJUDO-Tremelimumab Injection, Solution, Available online: https:\/\/dailymed.nlm.nih.gov\/dailymed\/drugInfo.cfm?setid=6690679c-be2f-4588-a2e4-89fff74dd6be."},{"key":"ref_228","unstructured":"Center for Drug Evaluation and Reasearch (2026, August 04). FDA Approves Durvalumab for Resectable Gastric or Gastroesophageal Junction Adenocarcinoma. FDA 2025, Available online: https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-durvalumab-resectable-gastric-or-gastroesophageal-junction-adenocarcinoma."},{"key":"ref_229","unstructured":"(2026, August 04). Search Orphan Drug Designations and Approvals, Available online: https:\/\/www.accessdata.fda.gov\/scripts\/opdlisting\/oopd\/detailedIndex.cfm?cfgridkey=738120."},{"key":"ref_230","unstructured":"(2026, August 04). Tevimbra|European Medicines Agency (EMA). Available online: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/tevimbra."},{"key":"ref_231","unstructured":"(2026, August 04). Search Orphan Drug Designations and Approvals, Available online: https:\/\/www.accessdata.fda.gov\/scripts\/opdlisting\/oopd\/detailedIndex.cfm?cfgridkey=708919."},{"key":"ref_232","unstructured":"(2026, August 04). Search Orphan Drug Designations and Approvals, Available online: https:\/\/www.accessdata.fda.gov\/scripts\/opdlisting\/oopd\/detailedIndex.cfm?cfgridkey=292409."},{"key":"ref_233","unstructured":"(2026, August 04). Herceptin|European Medicines Agency (EMA). Available online: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/herceptin."},{"key":"ref_234","unstructured":"Center for Drug Evaluation and Reasearch (2026, August 04). FDA Approves Fam-Trastuzumab Deruxtecan-Nxki for HER2-Positive Gastric Adenocarcinomas. FDA 2021, Available online: https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-fam-trastuzumab-deruxtecan-nxki-her2-positive-gastric-adenocarcinomas."},{"key":"ref_235","unstructured":"(2026, August 04). Enhertu|European Medicines Agency (EMA). Available online: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/enhertu."},{"key":"ref_236","unstructured":"Center for Drug Evaluation and Reasearch (2026, August 04). FDA Grants Accelerated Approval to Fam-Trastuzumab Deruxtecan-Nxki for Unresectable or Metastatic HER2-Positive Solid Tumors. FDA 2024, Available online: https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-grants-accelerated-approval-fam-trastuzumab-deruxtecan-nxki-unresectable-or-metastatic-her2."},{"key":"ref_237","unstructured":"Center for Drug Evaluation and Reasearch (2026, August 04). FDA Grants Accelerated Approval to Zanidatamab-Hrii for Previously Treated Unresectable or Metastatic HER2-Positive Biliary Tract Cancer. FDA 2024, Available online: https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-grants-accelerated-approval-zanidatamab-hrii-previously-treated-unresectable-or-metastatic-her2."},{"key":"ref_238","unstructured":"(2026, August 04). Ziihera|European Medicines Agency (EMA). Available online: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/ziihera."},{"key":"ref_239","unstructured":"Center for Drug Evaluation and Reasearch (2026, August 04). FDA Approves Zolbetuximab-Clzb with Chemotherapy for Gastric or Gastroesophageal Junction Adenocarcinoma. FDA 2024, Available online: https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-zolbetuximab-clzb-chemotherapy-gastric-or-gastroesophageal-junction-adenocarcinoma."},{"key":"ref_240","unstructured":"(2026, August 04). Vyloy|European Medicines Agency (EMA). Available online: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/vyloy."},{"key":"ref_241","unstructured":"(2026, August 04). DailyMed-AVASTIN-Bevacizumab Injection, Solution, Available online: https:\/\/dailymed.nlm.nih.gov\/dailymed\/drugInfo.cfm?setid=939b5d1f-9fb2-4499-80ef-0607aa6b114e."},{"key":"ref_242","unstructured":"(2026, August 04). Avastin|European Medicines Agency (EMA). Available online: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/avastin."},{"key":"ref_243","unstructured":"(2026, August 04). Search Orphan Drug Designations and Approvals, Available online: https:\/\/www.accessdata.fda.gov\/scripts\/opdlisting\/oopd\/detailedIndex.cfm?cfgridkey=359711."},{"key":"ref_244","unstructured":"(2026, August 04). Cyramza|European Medicines Agency (EMA). Available online: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/cyramza."},{"key":"ref_245","unstructured":"(2026, August 04). DailyMed-CYRAMZA-Ramucirumab Solution, Available online: https:\/\/dailymed.nlm.nih.gov\/dailymed\/drugInfo.cfm?setid=c6080942-dee6-423e-b688-1272c2ae90d4."},{"key":"ref_246","unstructured":"(2026, August 04). Search Orphan Drug Designations and Approvals, Available online: https:\/\/www.accessdata.fda.gov\/scripts\/opdlisting\/oopd\/detailedIndex.cfm?cfgridkey=353911."},{"key":"ref_247","unstructured":"(2026, August 04). DailyMed-ZALTRAP-Ziv-Aflibercept Solution, Concentrate, Available online: https:\/\/dailymed.nlm.nih.gov\/dailymed\/drugInfo.cfm?setid=f6725df6-50ee-4b0a-b900-d02ba634395d."},{"key":"ref_248","unstructured":"(2026, August 04). Zaltrap|European Medicines Agency (EMA). Available online: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/zaltrap."},{"key":"ref_249","unstructured":"(2026, August 04). DailyMed-ERBITUX-Cetuximab Solution, Available online: https:\/\/dailymed.nlm.nih.gov\/dailymed\/drugInfo.cfm?setid=8bc6397e-4bd8-4d37-a007-a327e4da34d9."},{"key":"ref_250","unstructured":"(2026, August 04). Erbitux|European Medicines Agency (EMA). Available online: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/erbitux."},{"key":"ref_251","unstructured":"(2026, August 04). DailyMed-VECTIBIX-Panitumumab Solution, Available online: https:\/\/dailymed.nlm.nih.gov\/dailymed\/drugInfo.cfm?setid=e0fa4bca-f245-4d92-ae29-b0c630a315c2."},{"key":"ref_252","unstructured":"(2026, August 04). Vectibix|European Medicines Agency (EMA). Available online: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/vectibix."},{"key":"ref_253","unstructured":"(2026, August 04). DailyMed-ERBITUX-Cetuximab Solution, Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2004\/125084lbl.pdf."},{"key":"ref_254","unstructured":"(2026, August 04). Braftovi|European Medicines Agency (EMA). Available online: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/braftovi."},{"key":"ref_255","unstructured":"Center for Drug Evaluation and Reasearch (2026, August 04). FDA Grants Accelerated Approval to Encorafenib with Cetuximab and mFOLFOX6 for Metastatic Colorectal Cancer with a BRAF V600E Mutation. FDA 2024, Available online: https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-grants-accelerated-approval-encorafenib-cetuximab-and-mfolfox6-metastatic-colorectal-cancer-braf."},{"key":"ref_256","unstructured":"(2026, August 04). Meeting Highlights from the Committee for Medicinal Products for Human Use (CHMP) 18\u201321 May 2026|European Medicines Agency (EMA). Available online: https:\/\/www.ema.europa.eu\/en\/news\/meeting-highlights-committee-medicinal-products-human-use-chmp-18-21-may-2026."},{"key":"ref_257","unstructured":"Center for Drug Evaluation and Reasearch (2026, August 04). FDA Grants Accelerated Approval to Adagrasib with Cetuximab for KRAS G12C-Mutated Colorectal Cancer. FDA 2024, Available online: https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-grants-accelerated-approval-adagrasib-cetuximab-kras-g12c-mutated-colorectal-cancer."},{"key":"ref_258","unstructured":"(2026, August 04). Krazati|European Medicines Agency (EMA). Available online: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/krazati."},{"key":"ref_259","unstructured":"Center for Drug Evaluation and Reasearch (2026, August 04). FDA Approves Sotorasib with Panitumumab for KRAS G12C-Mutated Colorectal Cancer. FDA 2025, Available online: https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-sotorasib-panitumumab-kras-g12c-mutated-colorectal-cancer."},{"key":"ref_260","unstructured":"(2026, August 04). Lumykras|European Medicines Agency (EMA). Available online: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/lumykras."},{"key":"ref_261","unstructured":"(2026, August 04). Search Orphan Drug Designations and Approvals, Available online: https:\/\/www.accessdata.fda.gov\/scripts\/opdlisting\/oopd\/detailedIndex.cfm?cfgridkey=624117."},{"key":"ref_262","unstructured":"(2026, August 04). Pemazyre|European Medicines Agency (EMA). Available online: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/pemazyre."},{"key":"ref_263","unstructured":"(2026, August 04). Search Orphan Drug Designations and Approvals, Available online: https:\/\/www.accessdata.fda.gov\/scripts\/opdlisting\/oopd\/detailedIndex.cfm?cfgridkey=635018."},{"key":"ref_264","unstructured":"(2026, August 04). Lytgobi|European Medicines Agency (EMA). Available online: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/lytgobi."},{"key":"ref_265","unstructured":"(2026, August 04). Search Orphan Drug Designations and Approvals, Available online: https:\/\/www.accessdata.fda.gov\/scripts\/opdlisting\/oopd\/detailedIndex.cfm?cfgridkey=562216."},{"key":"ref_266","unstructured":"(2026, August 04). Tibsovo|European Medicines Agency (EMA). Available online: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/tibsovo."},{"key":"ref_267","unstructured":"(2026, August 04). Search Orphan Drug Designations and Approvals, Available online: https:\/\/www.accessdata.fda.gov\/scripts\/opdlisting\/oopd\/detailedIndex.cfm?cfgridkey=655318."},{"key":"ref_268","unstructured":"(2026, August 04). Lynparza|European Medicines Agency (EMA). Available online: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/lynparza."},{"key":"ref_269","unstructured":"Center for Drug Evaluation and Reasearch (2026, August 04). FDA Approves Larotrectinib for Solid Tumors with NTRK Gene Fusions. FDA 2019, Available online: https:\/\/www.fda.gov\/drugs\/fda-approves-larotrectinib-solid-tumors-ntrk-gene-fusions."},{"key":"ref_270","unstructured":"(2026, August 04). Vitrakvi|European Medicines Agency (EMA). Available online: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/vitrakvi."},{"key":"ref_271","unstructured":"(2026, August 04). Center for Drug Evaluation and Reasearch, FDA Expands Pediatric Indication for Entrectinib and Approves New Pellet Formulation. FDA 2024, Available online: https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-expands-pediatric-indication-entrectinib-and-approves-new-pellet-formulation."},{"key":"ref_272","unstructured":"(2026, August 04). Rozlytrek|European Medicines Agency (EMA). Available online: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/rozlytrek."},{"key":"ref_273","unstructured":"Center for Drug Evaluation and Reasearch (2026, August 04). FDA Grants Accelerated Approval to Dostarlimab-Gxly for dMMR Advanced Solid Tumors. FDA 2024, Available online: https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-grants-accelerated-approval-dostarlimab-gxly-dmmr-advanced-solid-tumors."},{"key":"ref_274","unstructured":"(2026, August 04). Jemperli|European Medicines Agency (EMA). Available online: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/jemperli."},{"key":"ref_275","doi-asserted-by":"crossref","first-page":"2261","DOI":"10.1056\/NEJMoa2200075","article-title":"Circulating Tumor DNA Analysis Guiding Adjuvant Therapy in Stage II Colon Cancer","volume":"386","author":"Tie","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_276","doi-asserted-by":"crossref","first-page":"3272","DOI":"10.1038\/s41591-024-03254-6","article-title":"ctDNA-Based Molecular Residual Disease and Survival in Resectable Colorectal Cancer","volume":"30","author":"Nakamura","year":"2024","journal-title":"Nat. Med."},{"key":"ref_277","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1038\/s41467-020-14310-3","article-title":"White Blood Cell and Cell-Free DNA Analyses for Detection of Residual Disease in Gastric Cancer","volume":"11","author":"Leal","year":"2020","journal-title":"Nat. Commun."},{"key":"ref_278","doi-asserted-by":"crossref","first-page":"6815","DOI":"10.1038\/s41467-025-62056-7","article-title":"Longitudinal Circulating Tumor DNA Analysis during Treatment of Locally Advanced Resectable Gastric or Gastroesophageal Junction Adenocarcinoma: The PLAGAST Prospective Biomarker Study","volume":"16","author":"Zaanan","year":"2025","journal-title":"Nat. Commun."},{"key":"ref_279","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1053\/j.gastro.2024.05.005","article-title":"Emerging Trends in Gastrointestinal Cancer Targeted Therapies: Harnessing Tumor Microenvironment, Immune Factors, and Metabolomics Insights","volume":"167","author":"Rauth","year":"2024","journal-title":"Gastroenterology"},{"key":"ref_280","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1038\/s41392-024-02021-w","article-title":"Liquid Biopsy in Cancer: Current Status, Challenges and Future Prospects","volume":"9","author":"Ma","year":"2024","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_281","doi-asserted-by":"crossref","first-page":"1438","DOI":"10.1021\/acsptsci.4c00677","article-title":"Innovative Immunotherapy and Its Transformative Impact on Gastric Adenocarcinoma: A Comprehensive Review of the Disease\u2019s Origins, Epidemiology, Classification, Diagnosis, and Treatment Options","volume":"8","author":"Upasana","year":"2025","journal-title":"ACS Pharmacol. Transl. Sci."},{"key":"ref_282","doi-asserted-by":"crossref","unstructured":"Myat, Y.M., Thein, K.Z., Han, M.M., Ahluwalia, M., Mukherjee, S., and Aung, K.L. (2026). Understanding the Promise and Challenges of Tumor-Agnostic Therapy: Could One Size Really Fit All?. Cancers, 18.","DOI":"10.3390\/cancers18101568"},{"key":"ref_283","doi-asserted-by":"crossref","first-page":"8120","DOI":"10.18632\/oncotarget.23429","article-title":"Efficacy and Safety of Targeting VEGFR Drugs in Treatment for Advanced or Metastatic Gastric Cancer: A Systemic Review and Meta-Analysis","volume":"9","author":"Liu","year":"2017","journal-title":"Oncotarget"},{"key":"ref_284","doi-asserted-by":"crossref","unstructured":"Santorsola, M., Capuozzo, M., Nasti, G., Sabbatino, F., Di Mauro, A., Di Mauro, G., Vanni, G., Maiolino, P., Correra, M., and Granata, V. (2024). Exploring the Spectrum of VEGF Inhibitors\u2019 Toxicities from Systemic to Intra-Vitreal Usage in Medical Practice. Cancers, 16.","DOI":"10.3390\/cancers16020350"},{"key":"ref_285","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1186\/s13045-021-01166-3","article-title":"Intratumor Heterogeneity: The Hidden Barrier to Immunotherapy against MSI Tumors from the Perspective of IFN-\u03b3 Signaling and Tumor-Infiltrating Lymphocytes","volume":"14","author":"Wu","year":"2021","journal-title":"J. Hematol. Oncol."},{"key":"ref_286","doi-asserted-by":"crossref","unstructured":"Hou, W., Yi, C., and Zhu, H. (2022). Predictive Biomarkers of Colon Cancer Immunotherapy: Present and Future. Front. Immunol., 13.","DOI":"10.3389\/fimmu.2022.1032314"},{"key":"ref_287","doi-asserted-by":"crossref","first-page":"100268","DOI":"10.1016\/j.esmogo.2025.100268","article-title":"Molecular Classification of Microsatellite-Instable Colorectal Cancers Reveals Distinct Predictors of Immunotherapy Response","volume":"10","author":"Lin","year":"2025","journal-title":"ESMO Gastrointest. Oncol."},{"key":"ref_288","doi-asserted-by":"crossref","unstructured":"Wang, Q., Yu, M., and Zhang, S. (2025). The Characteristics of the Tumor Immune Microenvironment in Colorectal Cancer with Different MSI Status and Current Therapeutic Strategies. Front. Immunol., 15.","DOI":"10.3389\/fimmu.2024.1440830"},{"key":"ref_289","doi-asserted-by":"crossref","first-page":"102411","DOI":"10.1016\/j.suronc.2026.102411","article-title":"Surgery and the Gastrointestinal Microbiome in Cancer: Bidirectional Impacts and Therapeutic Opportunities\u2014A Narrative Review","volume":"66","author":"Horvath","year":"2026","journal-title":"Surg. Oncol."},{"key":"ref_290","doi-asserted-by":"crossref","unstructured":"Ronellenfitsch, U. (2023). Surgical Treatment of Gastrointestinal Cancers. Cancers, 15.","DOI":"10.3390\/cancers15143743"},{"key":"ref_291","doi-asserted-by":"crossref","unstructured":"Fabbi, M., Bali, C.D., Lianos, G.D., and Rausei, S. (2024). Treatment of Gastric Cancer Means Surgery, but Not Surgery Alone. Cancers, 16.","DOI":"10.3390\/cancers16081601"},{"key":"ref_292","doi-asserted-by":"crossref","unstructured":"Sato, Y., Okamoto, K., Kawano, Y., Kasai, A., Kawaguchi, T., Sagawa, T., Sogabe, M., Miyamoto, H., and Takayama, T. (2023). Novel Biomarkers of Gastric Cancer: Current Research and Future Perspectives. J. Clin. Med., 12.","DOI":"10.3390\/jcm12144646"},{"key":"ref_293","doi-asserted-by":"crossref","unstructured":"Saoudi Gonzalez, N., Patelli, G., and Crisafulli, G. (2025). Clinical Actionability of Genes in Gastrointestinal Tumors. Genes, 16.","DOI":"10.3390\/genes16101130"},{"key":"ref_294","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1186\/s13062-022-00322-0","article-title":"The Current State of Molecular Profiling in Gastrointestinal Malignancies","volume":"17","author":"Mukherji","year":"2022","journal-title":"Biol. Direct"},{"key":"ref_295","doi-asserted-by":"crossref","unstructured":"Han, D.M., Wakefield, M.R., and Fang, Y. (2025). Beyond Detection: Conventional and Emerging Biomarkers in Gastrointestinal Cancers. Cancers, 17.","DOI":"10.3390\/cancers17172725"},{"key":"ref_296","doi-asserted-by":"crossref","first-page":"2269","DOI":"10.1097\/MS9.0000000000004777","article-title":"Global Research Trends in Diagnostic Biomarkers for Colorectal Cancer: A Bibliometric and Visualization Analysis","volume":"88","author":"Gao","year":"2026","journal-title":"Ann. Med. Surg."},{"key":"ref_297","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1007\/s40259-025-00727-z","article-title":"Beyond Cost: Observations on Clinical and Patient Benefits of Biosimilars in Real-World Settings","volume":"39","author":"Kvien","year":"2025","journal-title":"BioDrugs"},{"key":"ref_298","doi-asserted-by":"crossref","first-page":"100116","DOI":"10.1016\/j.hpopen.2024.100116","article-title":"The Evolving Value Assessment of Cancer Therapies: Results from a Modified Delphi Study","volume":"6","author":"Lee","year":"2024","journal-title":"Health Policy OPEN"},{"key":"ref_299","doi-asserted-by":"crossref","first-page":"2453","DOI":"10.3390\/curroncol31050184","article-title":"New Anticancer Drugs: Reliably Assessing \u201cValue\u201d While Addressing High Prices","volume":"31","author":"Stewart","year":"2024","journal-title":"Curr. Oncol."},{"key":"ref_300","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1093\/annonc\/mdv249","article-title":"A Standardised, Generic, Validated Approach to Stratify the Magnitude of Clinical Benefit That Can Be Anticipated from Anti-Cancer Therapies: The European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS)","volume":"26","author":"Cherny","year":"2015","journal-title":"Ann. Oncol."},{"key":"ref_301","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1016\/j.annonc.2025.04.006","article-title":"ESMO-Magnitude of Clinical Benefit Scale Version 2.0 (ESMO-MCBS v2.0)","volume":"36","author":"Cherny","year":"2025","journal-title":"Ann. Oncol."}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/18\/16\/2675\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T04:11:47Z","timestamp":1787285507000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/18\/16\/2675"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,18]]},"references-count":301,"journal-issue":{"issue":"16","published-online":{"date-parts":[[2026,8]]}},"alternative-id":["cancers18162675"],"URL":"https:\/\/doi.org\/10.3390\/cancers18162675","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,18]]}}}